<PAGE>


                     U.S. SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

                    QUARTERLY REPORT FOR THE QUARTERLY PERIOD
                               ENDED JUNE 30, 2002

                           COMMISSION FILE NO. 0-28077

                                 GENELINK, INC.
                 ----------------------------------------------
                 (Name of Small Business Issuer in its charter)

        PENNSYLVANIA                                     23-2795613
        ------------                                   -------------
   (State or other jurisdiction of          (I.R.S. Employer Identification No.)
   incorporation or organization)


        100 S. Thurlow Street
          Margate, New Jersey                                        08402
  ------------------------------------                             ----------
(Address of principal executive offices)                           (Zip Code)

                    ISSUER'S TELEPHONE NUMBER: (609) 823-6991



         Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes X No ___

         APPLICABLE ONLY TO CORPORATE ISSUERS: Indicate the number of shares
outstanding of each of the issuer's classes of common stock, as of the latest
practicable date.

<TABLE>
<S>                                                         <C>
       Number of Shares of Common Stock
       Outstanding on August 6, 2002                        18,054,752
                                                            ---------
</TABLE>

      Transitional Small Business Disclosure Format        Yes ___  No X
<PAGE>
PART I.  FINANCIAL INFORMATION

ITEM 1.  Financial Statements.

         Balance Sheets at June 30, 2002 (unaudited) and December 31, 2001

         Statements of Income for the three months and six months ended June 30,
         2002 and 2001 (unaudited)

         Statements of Cash Flows for the six months ended June 30, 2002 and
         2001 (unaudited)

         Notes to Interim Financial Statements

                                       2
<PAGE>
                                 GENELINK, INC.
                                 BALANCE SHEETS

<TABLE>
<CAPTION>
                                                  (Unaudited)
                                                     June 30,          December 31,
                                                       2002               2001
                                                   -----------         -----------
<S>                                               <C>                  <C>
ASSETS
  Cash                                             $     4,021         $   121,434
  Accounts receivable                                      471               1,448
  Inventory                                              9,305              10,089
  Prepaid expenses                                     102,792             152,878
                                                   -----------         -----------
       TOTAL CURRENT ASSETS                            116,589             285,849

  Property and equipment                                63,585              55,662
  Advance to related party                             181,982                   0
  Other assets                                          32,947              23,881
                                                   -----------         -----------
TOTAL ASSETS                                       $   395,103         $   365,392
                                                   ===========         ===========

LIABILITIES

  Accounts payable and accrued expenses            $   102,538         $    88,816
  Accrued payroll taxes                                 51,977              11,593
  Customer deposits                                      5,000                   0
                                                   -----------         -----------
       TOTAL CURRENT LIABILITIES                       159,515             100,409

  Accrued compensation                                 297,373             357,807
  Loans payable-affiliates                              53,000              58,000
                                                   -----------         -----------
       TOTAL LIABILITIES                               509,888             516,216
                                                   -----------         -----------

STOCKHOLDERS' EQUITY (DEFICIT)
  Common stock, $.01 par value,
     75,000,000 shares authorized
     17,860,930 and 16,801,590 shares
     issued, 17,664,750 and 16,705,410
     outstanding as of June 30, 2002
     and December 31, 2001, respectively               178,608             168,015
  Treasury stock, 196,180 and 96,180
     shares as of June 30, 2002 and
     December 31, 2001, respectively                  (205,860)           (109,860)
  Additional paid-in capital                         5,701,069           5,279,271
  Stock subscriptions receivable                      (949,700)           (920,189)
  Stock warrants                                       576,254             350,334
  Deferred compensation                                      0            (200,000)
  Accumulated deficit                               (5,415,156)         (4,718,395)
                                                   -----------         -----------
       TOTAL STOCKHOLDERS' EQUITY (DEFICIT)           (114,785)           (150,824)
                                                   -----------         -----------
TOTAL LIABILITIES AND

  STOCKHOLDERS' EQUITY (DEFICIT)                   $   395,103         $   365,392
                                                   ===========         ===========
</TABLE>


    The accompanying notes are an integral part of the financial statements.


                                       3
<PAGE>
                                 GENELINK, INC.
                             STATEMENT OF OPERATIONS
                                   (UNAUDITED)
<TABLE>
<CAPTION>
                                                      For The            For The            For The              For The
                                                   Three Months       Three Months        Six Months            Six Months
                                                      Ended              Ended              Ended                  Ended
                                                   June 30, 2002      June 30, 2001      June 30, 2002         June 30, 2001
                                                   -------------      -------------      -------------         -------------
<S>                                                <C>                 <C>                 <C>                 <C>
REVENUE                                            $      2,409        $      5,668        $      8,258        $     11,462
COST OF GOODS SOLD                                          331                 615               1,234               1,224
                                                   ------------        ------------        ------------        ------------
GROSS PROFIT                                              2,078               5,053               7,024              10,238
                                                   ------------        ------------        ------------        ------------

EXPENSES

         Selling, general and administrative            171,788              86,029             477,630             393,246
         Consulting                                      62,116              32,221             103,522              51,192
         Professional fees                               42,300              12,936              65,088              62,587
         Advertising and promotion                       28,799              15,671              53,143              25,280
         Amortization and depreciation                    2,412               1,006               4,402               2,013
                                                   ------------        ------------        ------------        ------------
                                                        307,415             147,863             703,785             534,318
                                                   ------------        ------------        ------------        ------------
INTEREST EXPENSE                                              0               4,884                   0              17,047
                                                   ------------        ------------        ------------        ------------
NET LOSS BEFORE EXTRAORDINARY ITEM                     (305,337)           (147,694)           (696,761)           (541,127)

EXTRAORDINARY ITEM - FORGIVENESS OF DEBT                      0                   0                   0              14,010
                                                   ------------        ------------        ------------        ------------
NET LOSS BEFORE PROVISION FOR
INCOME TAXES                                           (305,337)           (147,694)           (696,761)           (527,117)
                                                   ------------        ------------        ------------        ------------
PROVISIONS FOR INCOME TAXES
                                                              0                   0                   0                   0
                                                   ------------        ------------        ------------        ------------

NET LOSS                                               (305,337)           (147,694)           (696,761)           (527,117)
                                                   ============        ============        ============        ============

NET LOSS PER SHARE BASIC AND DILUTED               $      (0.02)       $      (0.01)       $      (0.04)              (0.05)
                                                   ============        ============        ============        ============
Weighted average common shares and diluted
potential common shares                              17,786,757          14,127,250          17,366,351          13,554,700
                                                   ============        ============        ============        ============
</TABLE>


    The accompanying notes are an integral part of the financial statements.


                                       4
<PAGE>
                                 GENELINK ,INC.
                            STATEMENTS OF CASH FLOWS
                                   (UNAUDITED)
<TABLE>
<CAPTION>

SIX MONTHS ENDED JUNE 30                                              2002             2001
----------------------------------------------------------------------------------------------
<S>                                                                <C>              <C>
CASH FLOWS FROM OPERATING ACTIVITIES

    Net loss                                                       $(696,761)       $(527,117)
Adjustments to reconcile net loss
       to net cash used by operating activities
       Depreciation and amortization                                   4,402            2,012
       Amortization of bond discount                                       0           36,243
       Fair value of compensation related to vested options          200,000          200,000
       Common stock issued for services                               64,360           23,589
       Fair value of options granted for consulting services          60,690            7,710
       Changes in operating assets and liabilities
          Accounts receivable                                            977               26
          Inventory                                                      784              189
          Prepaid expenses                                            20,086            4,964
          Deposits                                                         0              112
          Accounts payable and accrued expenses                       13,720           29,996
          Accrued payroll taxes                                       40,384            9,389
          Customer deposits                                            5,000                0
          Accrued interest                                                 0           13,142
          Accrued compensation                                       (60,434)         100,287
                                                                   ---------        ---------
Net cash used by operating activities                               (346,792)         (99,458)
                                                                   ---------        ---------

CASH FLOWS FROM INVESTING ACTIVITIES

   Capital expenditures                                              (21,389)               0
   Advance to related party                                         (181,982)               0
                                                                   ---------        ---------
Net cash used by investing activities                               (203,371)               0
                                                                                    ---------

CASH FLOWS FROM FINANCING ACTIVITIES

   Proceeds from loans payable                                             0            4,770
   Repayments of loan payable                                         (5,000)               0
   Proceeds relating to issuance of common stock (net)               437,750           85,000
                                                                   ---------        ---------
Net cash provided by financing activities                          $ 432,750        $  89,770
                                                                   ---------        ---------
</TABLE>


    The accompanying notes are an integral part of the financial statements.


                                       5
<PAGE>
                                 GENELINK ,INC.
                            STATEMENTS OF CASH FLOWS
                                   (UNAUDITED)

<TABLE>
<CAPTION>
SIX MONTHS ENDED JUNE 30                                       2002             2001
--------------------------------------------------------------------------------------
<S>                                                         <C>              <C>
NET DECREASE IN CASH AND CASH EQUIVALENTS                   $(117,413)       $  (9,688)

Cash and cash equivalents beginning of period                 121,434           13,804
                                                            ---------        ---------

Cash and cash equivalents end of period                     $   4,021        $   4,116
                                                            =========        =========

SUPPLEMENTAL CASH FLOW INFORMATION

     Income taxes paid                                      $       0        $       0
                                                            =========        =========
     Interest paid                                          $       0        $       0
                                                            =========        =========

NON-CASH FINANCING TRANSACTIONS:
     Conversion of debt and accrued interest to stock               0          506,112
     Accrued interest on subscriptions receivable              30,949           25,656
     Issuance of common stock for services                     64,360                0
     Acquisition of treasury stock                             96,000                0
     Conversion of accounts payable to stock                        0           30,000
</TABLE>


    The accompanying notes are an integral part of the financial statements.


                                       6
<PAGE>
                                 GENELINK, INC.
                      NOTES TO INTERIM FINANCIAL STATEMENTS

===============================================================================

         1 - DESCRIPTION OF
             ORGANIZATION

                                    BUSINESS ORGANIZATION

                                    GeneLink, Inc. (the Company), operating in
                                    New Jersey, was organized under the laws of
                                    the Commonwealth of Pennsylvania to offer to
                                    the public the safe collection and
                                    preservation of a family's DNA material for
                                    later use by the family to determine genetic
                                    linkage. The Company is the successor by
                                    merger to a Delaware corporation organized
                                    under the same name on September 21, 1994.
                                    The Company's executive offices are located
                                    in Margate, New Jersey.

                                    BUSINESS DESCRIPTION

                                    The Company was founded in response to the
                                    information being generated in the field of
                                    human molecular genetics. Management
                                    believes future generations could benefit
                                    from the DNA store of knowledge, as
                                    scientists are discovering an increasing
                                    number of connections between genes and
                                    specific diseases. For this reason, the
                                    Company has created a DNA banking service
                                    that stores DNA before and after an
                                    individual dies. This genetic history can
                                    help families determine if they are at risk
                                    for certain inherited diseases. DNA banking
                                    shifts the emphasis from diagnosis and
                                    treatment to detection and prevention.

                                    The Company has developed a patented DNA
                                    Collection Kit for the collection of DNA
                                    specimens of its clients. The DNA will be
                                    stored for 75-year intervals. Upon a
                                    client's request, and upon the payment of a
                                    retrieval fee, the stored DNA specimen can
                                    be retrieved and sent to a laboratory for
                                    testing.

                                    The Company has also developed three
                                    proprietary genetic indicator tests
                                    (GeneLink's Genesis 1 Program) and has filed
                                    three patent applications. These tests are
                                    designed to measure genes that can
                                    contribute to disease and aging, predict an
                                    individual's risk for skin aging, and
                                    predict an individual's susceptibility to
                                    obesity. The Company's patented DNA
                                    Collection Kit will be used for the Program,
                                    which can assist nutritional companies and
                                    medical, health and anti-aging practitioners
                                    to offer a "more targeted" and improved
                                    approach to wellness/nutritional therapies.



                                       7
<PAGE>
                                 GENELINK, INC.
                      NOTES TO INTERIM FINANCIAL STATEMENTS

===============================================================================

         2 - BASIS OF
             PRESENTATION

                                    The accompanying unaudited financial
                                    statements have been prepared by the Company
                                    in accordance with the instructions to Form
                                    10-QSB and Article 10 of Regulation S-X
                                    relating to interim financial statements.
                                    Accordingly, they do not include all of the
                                    information and footnotes required by
                                    generally accepted accounting principles for
                                    complete financial statements and should be
                                    read in conjunction with the financial
                                    statements and notes thereto included in the
                                    Annual Report on Form 10-KSB of GeneLink,
                                    Inc. for the year ended December 31, 2001.

                                    In the opinion of management, all
                                    adjustments (consisting of normal recurring
                                    accruals) necessary to present fairly the
                                    information set forth in the accompanying
                                    financial statements have been included. The
                                    results reported in these financial
                                    statements for the three-month period and
                                    six month period ended June 30, 2002 should
                                    not be regarded as necessarily indicative of
                                    results that may be expected for the year
                                    ended December 31, 2002.

         3 - INCOME TAXES

                                    At June 30, 2002, the Company had
                                    significant federal and state tax net
                                    operating loss carryforwards of
                                    approximately $6,830,000. The difference
                                    between the operating loss carryforwards on
                                    a tax basis and a book basis is due
                                    principally to differences in depreciation,
                                    amortization, and treatment of stock
                                    options. The federal carryforwards will
                                    begin to expire in 2009 and the state
                                    carryforwards will begin to expire in 2005.

                                    The Company had a net deferred tax asset of
                                    $773,000 at June 30, 2002 primarily from net
                                    operating loss carryforwards. A valuation
                                    allowance was recorded to reduce the net
                                    deferred tax asset to zero.

         4 - SHAREHOLDERS'
             EQUITY TRANSACTIONS

                                    COMMON STOCK

                                    During the six months ended June 30, 2002,
                                    the Company issued 568,000 shares of common
                                    stock and 568,000 warrants to purchase
                                    common stock for an aggregate cash
                                    consideration of $355,000. This is pursuant
                                    to the private placement offering from June,
                                    2001 and subsequent amendments in 2001.
                                    Using the Black-Scholes methodology, the
                                    warrants were valued at $225,920.


                                       8
<PAGE>
                                 GENELINK, INC.
                      NOTES TO INTERIM FINANCIAL STATEMENTS

===============================================================================

                                    In addition to the private placement, the
                                    Company issued an additional 400,000 shares
                                    of common stock for an aggregate cash
                                    consideration of $135,000 during the six
                                    months ended June 30, 2002.

                                    The Company issued 91,340 shares of common
                                    stock for services rendered, valued at
                                    $64,360 for the six months ended June 30,
                                    2002.

                                    STOCK OPTIONS AND WARRANTS

                                    During the six months ended June 30, 2002,
                                    an officer of the Company was granted
                                    options to acquire 1,200,000 shares of
                                    common stock at $.82 per share. The options
                                    vest in three equal annual installments
                                    beginning in April, 2003.

                                    With respect to stock options granted to
                                    officers of the Company in 1997, $200,000 of
                                    deferred compensation was amortized during
                                    the six months ended June 30, 2002.

                                    During the six months ended June 30, 2002,
                                    $52,250 and $8,440 was charged against
                                    additional paid in capital and consulting
                                    fees, respectively, for options vested
                                    during the quarter that were issued in prior
                                    years pursuant to consulting agreements.

                                    TREASURY STOCK

                                    During the six months ended June 30, 2002,
                                    100,000 shares of common stock valued at
                                    $96,000 was returned to the Company and
                                    recorded as treasury stock. The stock was
                                    issued during 2001 for services rendered.

         5 - TRANSACTIONS
             WITH RELATED
             PARTIES

                                    Pursuant to employment and consulting
                                    agreements with two officers, compensation
                                    of $131,436 was accrued during the six
                                    months ended June 30, 2002.

                                    During the six months ended June 30, 2002,
                                    the Company paid John R. DePhillipo, the
                                    Chief Executive Officer and President of the
                                    Company, $191,870 of the $280,713 accrued
                                    compensation owed to him.

                                    COMMITMENT

                                    On April 24, 2002, the Company entered into
                                    a Distribution Agreement with NuGenix, LLC
                                    ("NuGenix"), pursuant to which it

                                       9
<PAGE>
                                 GENELINK, INC.
                      NOTES TO INTERIM FINANCIAL STATEMENTS

===============================================================================

                                    granted NuGenix the right to distribute
                                    vitamin and nutritional supplement products
                                    and regimens developed utilizing the
                                    Company's proprietary genetic profiling
                                    technology (the "Products") in the direct
                                    selling market with North America. The
                                    Distribution Agreement grants to NuGenix an
                                    exclusive right through January 31, 2003 and
                                    a non-exclusive right for a period of five
                                    years thereafter to market and sell the
                                    Products within North America through the
                                    direct selling market.

                                    In connection with entering into the
                                    Distribution Agreement, the Company has
                                    agreed to loan NuGenix $500,000 to fund
                                    NuGenix's operations, of which $180,000 was
                                    lent by the Company to NuGenix on April 24,
                                    2002. The loan is for a three year term,
                                    accrues interest at the rate of six percent
                                    (6%) per year and grants the Company the
                                    right to convert the principal balance of
                                    the loan into an equity position in NuGenix.
                                    To secure NuGenix's obligations with respect
                                    to the loan, NuGenix has granted the Company
                                    a first priority security interest in all of
                                    its assets and the members of NuGenix have
                                    pledged their membership interests in
                                    NuGenix to the Company. NuGenix is entirely
                                    owned by DePhillipo Family, LLC, which in
                                    turn is owned by the adult children of John
                                    R. DePhillipo, the Chief Executive Officer
                                    and President and a member of the Board of
                                    Directors of the Company.


                                       10
<PAGE>
ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
         RESULTS OF OPERATIONS

Statements in this Report that relate to future results and events are based on
the Company's current expectations. Actual results in future periods may differ
materially from those currently expected or desired because of a number of risks
and uncertainties. For a discussion of factors affecting the Company's business
and prospects, see "Item 2 - Management's Discussion and Analysis of Financial
Condition and Results of Operations - Factors Affecting the Company's Business
and Prospects."

Operating results for the six-month period ended June 30, 2002 are not
necessarily indicative of the results that may be expected for the full fiscal
year.

LIQUIDITY AND CAPITAL RESOURCES

For the six month period ended June 30, 2002, the Company's primary liquidity
requirements have been funding NuGenix, LLC ("NuGenix") pursuant to the
obligations entered into in connection with NuGenix becoming a distributor for
the Company, the implementation and funding of its sales and marketing efforts,
the funding of its research and development efforts, the payment of compensation
to officers and other employees and the payment of accounts payable. In the
first six months of 2002, the Company has raised $437,750, primarily through the
issuance of common stock.

Cash and cash equivalents at June 30, 2002 amounted to $4,021 as compared to
$121,434 at December 31, 2001, a decrease of $117,413. During the first six
months of 2002, the Company's operating activities utilized $346,792, as
compared to $99,458 for the first six months of 2001. Cash utilized during these
periods resulted from Company's net losses for such periods.

Financing activities provided $432,750 for the six month period ended June 30,
2002 as compared to $89,770 for the six months ended June 30, 2001. Financing
activities in the six months ended June 30, 2002 resulted primarily from the
receipt of $437,750 as a result of the issuance of common stock throughout the
first six months of 2002, as the Company required additional funds for working
capital purposes.

The Company will require approximately $1,000,000 in 2002 to fund NuGenix, to
fund research and development expenses and to pay accounts payable. The Company
intends to raise funds through a private placement of securities. Unless the
Company can increase its revenues and increase its stock price, it is unlikely
that the Company will be able to secure such financing. If the Company is not
able to secure such additional required capital, it will continue to realize
negative cash flow and losses and it is unlikely that it will be able to
continue operations.


                                       11
<PAGE>
RESULTS OF OPERATIONS

The following table sets forth certain operating information regarding the
Company:

<TABLE>
<CAPTION>
                                            SIX MONTH               SIX MONTH
                                            PERIOD ENDED            PERIOD ENDED
                                            JUNE 30, 2002           JUNE 30, 2001

                                           (UNAUDITED)                (UNAUDITED)
                                           -----------                -----------
<S>                                         <C>                      <C>
Revenues                                    $   8,258                $  11,462

Cost of Goods Sold                          $   1,234                $   1,224

Net Earnings (Loss)                         $(696,761)               $(527,117)

Net Earnings (Loss) Per Share               $    (.04)               $    (.05)
</TABLE>


      The following summary table presents comparative cash flows of the Company
for the six months ended June 30, 2002 and 2001.

<TABLE>
<CAPTION>
                                          SIX MONTH                  SIX MONTH
                                          PERIOD ENDED            PERIOD ENDED
                                          JUNE 30, 2002           JUNE 30, 2001

                                         (UNAUDITED)               (UNAUDITED)
                                         -----------              -------------
<S>                                      <C>                      <C>
Net cash used in operating
activities                               $ 346,792                $  99,458

Net cash used by
investing activities                     $(203,371)               $       0

Net cash provided by
financing activities                     $ 432,750                $  89,770
</TABLE>


      The Company had cash balances totaling $4,021 at June 30, 2002 and $4,116
at June 30, 2001.


                                       12
<PAGE>
COMPARISON OF SIX MONTHS ENDED JUNE 30, 2002 TO SIX MONTHS ENDED JUNE 30, 2001

FINANCIAL CONDITION

Assets of the Company increased from $365,392 at December 31, 2001 to $395,103
at June 30, 2002, an increase of $29,711. This increase was primarily due to an
increase in advances to related party from $0 at December 31, 2001 to $181,982
at June 30, 2002, as partially offset by a decrease in cash from $121,434 at
December 31, 2001 to $4,021 at June 30, 2002 and a decrease prepaid expenses
from $152,818 at December 31, 2001 to $102, 792 at June 30, 2002.

Liabilities decreased from $516,216 at December 31, 2001 to $509,888 at June 30,
2002, a decrease of $6,328. This decrease was primarily due to a decrease in
accrued compensation from $357,807 at December 31, 2001 to $297,373 at June 30,
2002, as partially offset by an increase in accounts payable from $88,816 at
December 31, 2001 to $102,538 at June 30, 2002 and an increase in accrued
payroll taxes from $11,593 at December 31, 2001 to $51,977 at June 30, 2002.

CURRENT YEAR PERFORMANCE AND EARNINGS OUTLOOK

Revenues. The total revenues for the six months ended June 30, 2002 were $8,258
as compared to $11,462 for the six months ended June 30, 2001, a decrease of
$3,204.

Expenses. Total expenses for the six months ended June 30, 2002 were $703,785 as
compared to $551,365 for the six months ended June 30, 2001, an increase of
$152,420, primarily resulting from the increase in selling general and
administrative expenses from $393,246 for the six months ended June 30, 2001 to
$477,630 for the six months ended June 30, 2002, an increase in consulting
expenses from $51,192 for the six months ended June 30, 2001 to $103,522 for the
six months ended June 30, 2002 and an increase in advertising and promotion
expenses from $25,280 for the six months ended December 30, 2001 to $53,145 for
the six months ended June 30, 2002, all related to the Company's efforts to
create a market for its proprietary genetic profiling technology.

Losses. The Company incurred a loss before extraordinary items of $696,761 for
the six months ended June 30, 2002 as compared to a loss of $541,127 for the six
months ended June 30, 2001, an increase of $155,634. This increase in the amount
of losses incurred is primarily due to the $152,420 increase in expenses
incurred by the Company for the six months ended June 30, 2002 as compared to
the six months ended June 30, 2001.


                                       13
<PAGE>
FACTORS AFFECTING THE COMPANY'S BUSINESS AND PROSPECTS

Statements included in this Report on Form 10-QSB, including within the
Management's Discussion and Analysis of Financial Condition and Results of
Operations which are not historical in nature, are intended to be and are hereby
identified as "forward looking statements" for purposes of the safe harbor
provided by the Private Securities Litigation Reform Act of 1995. Forward
looking statements are subject to certain risks and uncertainties that could
cause actual results to differ materially from those indicated in the forward
looking statements due to several factors. The Company undertakes no obligation
to publicly release any revisions to these forward looking statements or reflect
events or circumstances after the date hereof.

There are a number of factors that affect the Company's business and the result
of its operations. These factors include general economic and business
conditions; the level of acceptance of the Company's products and services; the
rate and commercial applicability of advancements and discoveries in the
genetics field; and the Company's ability to enter into strategic alliances with
companies in the genetics industry; the ability of the Company to raise the
financing necessary to implement its business and marketing plan, to pay
salaries to its officers and employees and to pay its accounts payable.


                                       14
<PAGE>
PART II. OTHER INFORMATION

Item 4.  Submission of Matters to a Vote of Security Holders

         The 2002 Annual Meeting of Shareholders of the Company was held on
April 29, 2002.

         At this meeting, the shareholders voted on the election of two
directors to hold office until the Annual Meeting of Shareholders in 2003 and
until their respective successors are duly elected and qualified.

         Votes were cast for the election of directors as follows, each of whom
continued in office after the meeting:

<TABLE>
<CAPTION>
                Nominee                 Votes For         Votes Withheld
                -------                 ---------         --------------
<S>                                    <C>                <C>
          John R. DePhillipo           12,333,755            2,306,790
          Robert P. Ricciardi          12,333,755            2,306,790
</TABLE>

Item 6.  Exhibits and Reports on Form 8-K.

         (a)      Exhibits

         99.1     Certification pursuant to 18 U.S.C. Section 1350, as adopted
         pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

         (b)      Reports on Form 8-K.

                  No reports on Form 8-K were filed during the quarter for which
                  this report is filed.

* * * * * *

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                 GENELINK, INC.
                                  (Registrant)


<TABLE>
<S>                                         <C>
Date: August 13, 2002                       By:     /s/ John R. DePhillipo
                                                    ---------------------------
                                                    John R. DePhillipo, Chief Executive
                                                    Officer and President
</TABLE>

                                       15